Stay updated with breaking news from Barbara Pistilli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Between a $28 million donation and launching an internship program, the distinguished company President stresses the importance of giving back.
Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.
Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.
Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.
Results from docetaxel-based study appear applicable to paclitaxel, nab-paclitaxel